Key result
Pre-procedural serum anti-M2-R presence was an independent predictor for the recurrence of atrial fibrillation one year after radiofrequency catheter ablation (OR 4.701).
Why the study?
Does pre-procedural serum anti-M2-R predict the recurrence of atrial fibrillation in patients undergoing radiofrequency catheter ablation?
Cohort (n=76)
No
Does pre-procedural serum anti-M2-R predict the recurrence of atrial fibrillation in patients undergoing radiofrequency catheter ablation?
Pre-procedural serum anti-M2-R levels independently predict the recurrence of atrial fibrillation one year after radiofrequency catheter ablation, suggesting its potential utility as a biomarker for risk stratification.
May aid pre-ablation AF risk stratification; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Increasing evidences have suggested that autoantibodies against muscarinic-2 acetylcholine receptor (anti-M2-R) may play an important role in the development of atrial fibrillation (AF). Predictive value of pre-procedural anti-M2-R for the recurrence of AF after radiofrequency catheter ablation is still unclear. METHODS: Totally 76 AF patients with preserved left ventricular systolic function were prospectively enrolled and subjected to ablation after the detection of serum anti-M2-R by enzyme linked immunosorbent assay. These patients were given follow-up examination for one year after ablation. Risk estimation for the recurrence of AF was performed using the univariate and multivariate logistic regression. RESULTS: In AF group, serum anti-M2-R was significantly higher than that in the control group in terms of frequency (40.8% versus 11.7%; p < 0.001) and titer (1:116 versus 1:29; p < 0.001). Compared with paroxysmal AF patients, persistent AF patients had higher frequency (57.6% versus 27.9%; p = 0.009) and titer (1:132 versus 1:94; p = 0.012) for autoantibodies. During one-year follow-up examination after ablation, the recurrence of AF was observed in 25 (32.9%) patients. Multivariate analysis showed that pre-procedural serum anti-M2-R was an independent predictor for the recurrence of AF at the time point of 12 months after ablation (odds ratio: 4.701; 95% confidence interval: 1.590-13.894; p = 0.005). CONCLUSIONS: In AF patients, the frequency and titer of serum anti-M2-R were significantly higher than those in the control group with sinus rhythm. Pre-procedural serum anti-M2-R was an independent predictor for the recurrence of AF one year after radiofrequency catheter ablation.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2013) conducted a cohort in Atrial fibrillation (n=76). Pre-procedural serum anti-M2-R (autoantibodies against M2-muscarinic acetylcholine receptor) vs. Absence of anti-M2-R was evaluated on Recurrence of atrial fibrillation at 12 months after ablation (OR 4.701, 95% CI 1.590-13.894, p=0.005). Pre-procedural serum anti-M2-R presence was an independent predictor for the recurrence of atrial fibrillation one year after radiofrequency catheter ablation (OR 4.701).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: